Industry Spotlight: Agilent Acquires BioTek

California-based Agilent, a leader in life sciences, diagnostics and applied chemical markets, has announced it has signed a definitive agreement to acquire privately owned-BioTek Instruments, a recognized global leader in design, manufacture and distribution of innovative life science instrumentation. 

 

The acquisition announcement comes after a more than year-long partnership between the companies. 

 

“BioTek represents a strong strategic fit with Agilent,” Mike McMullen, president and CEO of Agilent said in a press release. “The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis.”

 

Agilent first entered the cell analysis segment in 2015 with the acquisition of Seahorse Bioscience and has continued to broaden their cell analysis portfolio through the acquisitions of Luxcel and ACEA. As of the time of the announcement, Agilent plans to continue operations in Vermont, where BioTek is currently located. 

 

“Agilent and BioTek share the same passion around delivering insights that help customers understand diseases and discover potential therapeutic solutions more efficiently and accurately,” Todd Christian, vice president and general manager of the Cell Analysis Division, to whom the BioTek team will report upon completion of this transaction, said in a statement. “I believe this is a great opportunity and an important step toward enhancing our leadership in cell analysis and truly puts us in a differentiated and even stronger position.”

 

The Lab World Group has used and affordable equipment from Agilent, BioTek, and more for sale. View our full inventory of used laboratory equipment here.